<DOC>
	<DOC>NCT01606748</DOC>
	<brief_summary>The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.</brief_summary>
	<brief_title>A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Have documented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that are resistant to standard therapy or for which no standard therapy is available May have measurable or nonmeasurable disease Have resolution to Grade 0 or 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCICTCAE 4.0) of all clinically significant toxic effects (other than alopecia) of prior chemotherapy, surgery, radiotherapy, or hormonal therapy Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1 Have adequate hepatic, hematologic and renal function If female, are surgically sterile, postmenopausal, or agree to be compliant with a highly effective contraceptive method during and for 6 months after the treatment period. If male, are surgically sterile or agree to be compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period Female participants of childbearing potential have a negative serum pregnancy test within 7 days prior to the first dose of study therapy Have received a systemic anticancer agent (including EGFR tyrosine kinase inhibitors) or device within 28 days prior to first dose of study therapy The most recent anticancer therapy received by the participant included either gemcitabine or cisplatin (or both) Have received radiotherapy within 14 days prior to first dose of study therapy Have received cytotoxic chemotherapy within 21 days prior to first dose of study therapy Are receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, or targeted therapy Are considered surgical candidates (with resectable disease) Have brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants Have narrowing of or blockage in large veins Have coronary artery disease or uncontrolled congestive heart failure Have uncontrolled angina pectoris, or experienced myocardial infarction within 6 months prior to first dose of study therapy Have an ongoing or active infection (requiring treatment), including active tuberculosis or known infection with the human immunodeficiency virus Have a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder Have known drug or alcohol abuse If female, are pregnant or breastfeeding Have had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study therapy Are currently enrolled in, or discontinued within the 30 days prior to first dose of study therapy from a clinical trial involving an investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
	<keyword>Solid Cancers</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>